Progenics Pharmaceuticals had its price target set to $15 by Cantor Fitzgerald. Cantor Fitzgerald has a Buy rating on the stock. Cantor Fitzgerald has struggled over the last year with its performance; however, Needham and Company hasn't.
The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.